Anti-CLM5/ CD300LD/ CD300D monoclonal antibody

Anti-CLM5/ CD300LD/ CD300D antibody for FACS & in-vivo assay

Target products collectionGo to CD300LD/CD300LD products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0208-Ab-1/ GM-Tg-hg-MP0208-Ab-2Anti-Human CD300LD monoclonal antibodyHuman
GM-Tg-rg-MP0208-Ab-1/ GM-Tg-rg-MP0208-Ab-2Anti-Rat CD300LD monoclonal antibodyRat
GM-Tg-mg-MP0208-Ab-1/ GM-Tg-mg-MP0208-Ab-2Anti-Mouse CD300LD monoclonal antibodyMouse
GM-Tg-cynog-MP0208-Ab-1/ GM-Tg-cynog-MP0208-Ab-2Anti-Cynomolgus/ Rhesus macaque CD300LD monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0208-Ab-1/ GM-Tg-felg-MP0208-Ab-2Anti-Feline CD300LD monoclonal antibodyFeline
GM-Tg-cang-MP0208-Ab-1/ GM-Tg-cang-MP0208-Ab-2Anti-Canine CD300LD monoclonal antibodyCanine
GM-Tg-bovg-MP0208-Ab-1/ GM-Tg-bovg-MP0208-Ab-2Anti-Bovine CD300LD monoclonal antibodyBovine
GM-Tg-equg-MP0208-Ab-1/ GM-Tg-equg-MP0208-Ab-2Anti-Equine CD300LD monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0208-Ab-1/ GM-Tg-hg-MP0208-Ab-2; GM-Tg-rg-MP0208-Ab-1/ GM-Tg-rg-MP0208-Ab-2;
GM-Tg-mg-MP0208-Ab-1/ GM-Tg-mg-MP0208-Ab-2; GM-Tg-cynog-MP0208-Ab-1/ GM-Tg-cynog-MP0208-Ab-2;
GM-Tg-felg-MP0208-Ab-1/ GM-Tg-felg-MP0208-Ab-2; GM-Tg-cang-MP0208-Ab-1/ GM-Tg-cang-MP0208-Ab-2;
GM-Tg-bovg-MP0208-Ab-1/ GM-Tg-bovg-MP0208-Ab-2; GM-Tg-equg-MP0208-Ab-1/ GM-Tg-equg-MP0208-Ab-2
Products NameAnti-CD300LD monoclonal antibody
Formatmab
Target NameCD300LD
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CD300LD benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species CLM5/ CD300LD/ CD300D VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0208
    Target NameCD300LD
    Gene ID100131439,703142
    Gene Symbol and SynonymsCD300D,CD300LD,CLM-4,CLM-5,CMRF35-A4,CMRF35A4
    Uniprot AccessionQ6UXZ3
    Uniprot Entry NameCLM5_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000204345
    Target ClassificationN/A

    The target: CD300LD, gene name: CD300LD, also named as CD300D, CLM-4, CMRF35-A4, CMRF35A4. Predicted to enable transmembrane signaling receptor activity and virus receptor activity. Predicted to be involved in immune system process. Predicted to act upstream of or within regulation of interleukin-6 production and regulation of tumor necrosis factor production. Predicted to be integral component of membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.